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Houston, Texas
Objectives This study was designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse
outcomes in diabetic patients with established heart failure (HF).
Background Despite the common coexistence of diabetes and HF, previous studies examining the association between
HbA1C and outcomes in this population have been limited and have reported discrepant results.
Methods We assessed the association between increasing quintiles (Q1 to Q5) of HbA1C and risk of death or risk of HF
hospitalization by conducting a retrospective study in a national cohort of 5,815 veterans with HF and diabetes
treated in ambulatory clinics at Veterans Affairs medical centers.
Results At 2 years of follow-up, death occurred in 25% of patients in Q1 (HbA1C 6.4%), 23% in Q2 (6.4%  HbA1c
7.1%), 17.7% in Q3 (7.1%  HbA1c 7.8%), 22.5% in Q4 (7.8%  HbA1c 9.0%), and 23.2% in Q5 (HbA1c
9.0%). After adjustment for potential confounders, the middle quintile (Q3) had reduced mortality when com-
pared with the lowest quintile (risk-adjusted hazard ratio: 0.73, 95% confidence interval: 0.61 to 0.88, p 
0.001). Hospitalization rates for HF at 2 years increased with increasing quintiles of HbA1C (Q1: 13.3%, Q2:
13.1%, Q3: 15.5%, Q4: 16.4%, and Q5: 18.2%), but this association was not statistically significant when ad-
justed for potential confounders.
Conclusions The association between mortality and HbA1C in diabetic patients with HF appears U-shaped, with the lowest
risk of death in those patients with modest glucose control (7.1%  HbA1C 7.8%). Future prospective studies
are necessary to define optimal treatment goals in these patients. (J Am Coll Cardiol 2009;54:422–8) © 2009
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.049o
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piabetes mellitus and heart failure (HF) are major health
roblems. There are nearly 5 million individuals who have
F and over 500,000 new cases are diagnosed each year in
he U.S. (1). It has been well-established that diabetes, a
isease that is increasing in prevalence (2), is a significant
isk factor for the development of cardiovascular disease (3)
nd amplifies the risk for the development of HF (4–6). In
ddition, HF itself is considered an insulin-resistant state
nd is associated with significant risk for the future devel-
rom the *Winters Center for Heart Failure Research and Section of Cardiology,
epartment of Medicine, Baylor College of Medicine, Houston, Texas; and the
Section of Cardiology and ‡Houston Center for Quality of Care and Utilization
tudies, Michael E. DeBakey V.A. Medical Center, Houston, Texas. This study was
upported in part by VA Health Services Research and Development Service grant #
IR 02-082-1 (to Dr. Deswal). Dr. Aguilar is a recipient of a National Institutes of
ealth Mentored Career Development Award (5K01-HL092585-02). The views
xpressed in this article are those of the authors and do not necessarily represent those
f the Department of Veteran Affairs.g
Manuscript received February 2, 2009; revised manuscript received April 3, 2009,
ccepted April 29, 2009.pment of diabetes (7). Given these relationships, it is
ot surprising that diabetes and HF commonly coexist.
he prevalence of diabetes in major HF trials is approx-
mately 20% to 30% (8), although recent data from an
cute HF registry suggest that the prevalence may be as
igh as 45% (9). Importantly, in cohorts of patients with
stablished HF, diabetes has been associated with in-
reased mortality and morbidity (10 –12). Given the
cope and growing burden of diabetes and HF, efforts to
nderstand risk factors contributing to this increased
azard are increasingly important.
See page 429
One potential risk factor associated with adverse out-
omes is poor glycemic control. Glycosylated hemoglobin
HbA1C) reflects the ambient blood glucose over the
receding 2 to 3 months, is used as an index of mean
lycemia (13), and serves as a treatment target in patients
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July 28, 2009:422–8 HbA1C and Mortality in Diabetic HFith diabetes (14). In individuals free of HF, elevated
bA1C has been associated with an increased risk of
dverse cardiovascular outcomes (15), including increased
isk of incident HF (16). Despite these data, studies
xamining the association between HbA1C and outcomes
n diabetic patients with established HF have been limited
nd have reported discrepant results (17,18). Therefore, we
ought to determine the association between HbA1C and total
ortality or HF hospitalization in a large, national cohort of
mbulatory diabetic patients with established HF.
ethods
tudy design and sample. We performed a retrospective
tudy of a national cohort of veterans with HF treated in
mbulatory clinics at Veterans Affairs (VA) medical centers
sing the VA External Peer Review Program (EPRP) data
etween October 2000 and September 30, 2002. As de-
cribed in detail previously (19,20), the sampling pool of
utpatients for EPRP included ambulatory patients with
ommon chronic diseases such as HF, diabetes, ischemic
eart disease, and chronic obstructive pulmonary disease
dentified by specific ICD-9 (International Classification of
iseases-Ninth Revision) codes. Abstractors reviewed elec-
ronic medical records for validation of sample selection
riteria, including documentation of a HF diagnosis in
utpatient records (20). The overall outpatient cohort for
he EPRP for this period included 21,794 outpatients with
F. Patient-level data from the EPRP HF cohort was
inked with 5 existing national VA databases to obtain
urther demographic, laboratory, pharmacy, and outcome
ata.
Individuals from the EPRP HF cohort who had diabetes,
s identified in the EPRP data (n  8,842), were prescribed
ypoglycemic medications in the pharmacy database (n 
,148) and had a recorded HbA1C level (in the laboratory
atabase) within 1 year before or up to 2 weeks after the
ndex outpatient visit were included for this analysis (n 
,815). Diabetic therapy was ascertained using pharmacy
ata and was based on prescriptions filled 90 days before or
0 days following the index outpatient visit. Baseline de-
ographics and concomitant cardiac medications were as-
essed at the index visit. A covariate that reflected diabetes
everity included a variable documenting a diabetic compli-
ation including neuropathy, nephropathy, retinopathy, or
eripheral vascular disease. For laboratory data, the most
ecent laboratory data within 1 year before and up to 2
eeks after the index clinic visit were used. Glomerular
ltration rate (GFR) was calculated using the 4-variable
odification of Diet in Renal Disease equation (21).
Individuals were classified into categories based on quin-
iles of HbA1C. The levels of HbA1C in each quintile were
s follows: quintile (Q)1: HbA1C 6.4%; Q2: 6.4%
HbA1C 7.1%; Q3: 7.1%  HbA1C 7.8%; Q4: 7.8%
HbA1C 9.0%, and Q5: HbA1C 9.0%. hThe primary outcome was
ime to death or time to hospi-
alization for HF over 2 years
fter the index outpatient visit.
omplete follow-up over the
-year period was available for all
articipants.
tatistical analysis. Differences
n baseline variables were ascer-
ained using chi-square tests for
ategorical variables and analysis
f variances for continuous vari-
bles. Two-sided p values 0.05
ere considered statistically sig-
ificant. Univariate and multiva-
iable Cox proportional hazards models were used to assess
he relationship between outcomes and quintiles of HbA1c
using Q1 as the reference group). In the Cox proportional
azards model for HF hospitalization, the patients were
ensored when they died. From 29 candidate variables
ollected at baseline (including diabetic therapy), separate
ultivariable Cox proportional hazards models for death
nd for hospitalization for HF were constructed using
orward stepwise selection with variables with p 0.1 being
ntered into the model. Variables common to both models
ncluded: left ventricular ejection fraction (LVEF), GFR,
emoglobin, hyponatremia, COPD, atrial fibrillation, race,
ancer, and previous HF hospitalization within the last 2
ears. The multivariable model for death also included main
ffects of age, gender, angiotensin-converting enzyme in-
ibitor or angiotensin II receptor blocker use, beta-blocker
se, statin use, peripheral vascular disease, dementia, sulfo-
ylurea use, and biguanide use. The multivariable model for
F hospitalization included diabetes with complications,
nsulin use, psychiatric disorders, and rheumatologic dis-
ase. Missing laboratory values (other than HbA1C) were
mputed using the median value of the study cohort for that
arameter (missing: 245 [4.2%] for serum sodium, 387
6.7%] for serum creatinine, 752 [12.9%] for total choles-
erol, and 1,035 [17.8%] for hemoglobin) and a dummy
ariable was used to indicate replacement of missing data.
odels including only patients without missing laboratory
ata yielded no significant change in overall results. Statis-
ical analysis was performed using Intercooled Stata 9.2 for
indows (StataCorp LP, College Station, Texas).
esults
he study cohort consisted of 5,815 diabetic patients
ith HF. The cohort, consistent with VA medical
enters population, was 94% men with a mean age of
9.2  9.2 years. The mean body mass index was 31.7 
.7 kg/m2. Thirty-five percent of patients had a previous
yocardial infarction. A total of 4,840 (83%) patients
Abbreviations
and Acronyms
EPRP  External Peer
Review Program
GFR  glomerular filtration
rate
HbA1C  glycosylated
hemoglobin
HF  heart failure
LVEF  left ventricular
ejection fraction
Q  quintile
VA  Veterans Affairsad a documented assessment of LVEF; of these pa-
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HbA1C and Mortality in Diabetic HF July 28, 2009:422–8ients, 54.5% had preserved or mildly reduced LVEF
LVEF 40%) and 45.5% had moderate or severely
educed ejection fraction.
The mean HbA1C level of the cohort was 7.75  1.7%.
atient characteristics for each quintile are shown in Table 1.
ndividuals in the lower quintiles tended to be older; to have
lower GFR, hemoglobin, and total cholesterol; and were
ore likely to have preserved LVEF. As the HbA1C
uintiles increased, there was an increased prevalence of
iabetic complications, and individuals were more likely to
equire a greater number of medications for glycemic
herapy and were more likely to be receiving insulin therapy.
ndividuals in the higher quintiles were more likely to
eceive angiotensin-converting enzyme inhibitors or angio-
ensin II receptor blockers and statins.
ortality. Over 2 years of follow-up, 316 (25.0%) Q1
linical CharacteristicsTable 1 Clinical Characteristics
Quintile 1
HbA1C <6.4%
(n  1,264)
Quintile 2
6.4% < HbA1C <7.1%
(n  1,152)
Age, yrs 70.5 9.3 70.5 9.0
Men 93.4 94.1
Race
White 76.0 75.4
Black 12.0 9.4
Other/unknown 12.0 15.3
BMI, kg/m2 31.3 6.9 31.7 6.6
SBP, mm Hg 131 21.4 131 20.5
LVEF
Normal or mildly reduced 48.0 48.7
Moderate or severely reduced 33.3 33.4
Unknown 18.7 17.9
Diabetes with complications 51.7 55.0
Peripheral vascular disease 22.2 23.7
Atrial fibrillation 29.3 28.3
Past myocardial infarction 34.7 33.5
Prior HF hospitalization within 2 yrs 17.7 14.7
COPD 29.5 28.0
Cancer 18.4 16.9
HbA1C 5.9 0.5 6.8 0.2
GFR, ml/min/m2 54.8 22.7 55.2 21.5
Hemoglobin, mg/dl 13.1 1.9 13.3 1.7
Cholesterol, mg/dl 166 39.0 168 36.4
Medications
Insulin 33.6 41.2
Sulfonylurea 63.9 60.7
Biguanide 20.4 25.1
TZD 7.9 10.7
Other diabetic therapy 1.0 1.6
Mean no. of diabetic drugs receiving 1.3 1.4
ACE/ARB 80.5 83.3
Beta-blocker 60.4 59.5
Statin 52.6 55.6
ata expressed as mean SD or %.
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; BMI  bod
lycosylated hemoglobin; HF heart failure; LVEF  left ventricular ejection fraction; SBP systolic batients, 265 (23.0%) Q2 patients, 193 (17.7%) Q3 patients, p69 (22.5%) Q4 patients, and 257 (23.2%) Q5 patients died
Fig. 1, Table 2). The unadjusted and adjusted hazard ratios
or death are shown in Table 2. Using Q1 as the reference
roup, the middle quintile (Q3) had significantly reduced
ortality (risk-adjusted hazard ratio [HR]: 0.73, 95% con-
dence interval [CI]: 0.61 to 0.88, p  0.001).
Given the crude U-shaped relationship between mortality
nd quintiles of HbA1C levels, additional analyses were
erformed with multivariable Cox proportional hazard
odels using the middle quintile (Q3) as the reference
roup. Compared with Q3, the other 4 quintiles had a
ignificantly increased risk of death over 2 years (Q1 risk-
djusted HR: 1.37 [95% CI: 1.14 to 1.64, p  0.001]; Q2
isk-adjusted HR: 1.31 [95% CI: 1.09 to 1.58, p  0.004];
4 risk-adjusted HR: 1.31 [95% CI: 1.09 to 1.58, p 
.004]; Q5 risk-adjusted HR: 1.45 [95% CI: 1.20 to 1.76,
Quintile 3
.1% < HbA1C <7.8%
(n  1,092)
Quintile 4
7.8% < HbA1C <9.0%
(n  1,198)
Quintile 5
HbA1C >9.0%
(n  1,109) p Value
69.6 8.9 68.8 9.1 66.2 9.9 0.001
92.8 94.6 92.6 0.25
0.001
77.7 75.9 71.8
10.7 11.3 16.6
11.6 12.9 11.6
31.8 6.4 31.7 6.6 32.1 7.0 0.05
132 21.8 131 21.5 132 22.2 0.18
0.001
45.5 44.5 39.5
37.9 40.1 45.5
16.6 15.4 15.1
57.8 62.2 64.1 0.001
21.6 25.3 27.0 0.02
29.0 27.9 28.9 0.94
37.1 36.1 33.0 0.21
16.8 18.7 22.3 0.001
24.6 26.0 25.5 0.05
16.9 15.8 14.3 0.08
7.5 0.2 8.4 0.3 10.5 1.7 0.001
55.3 21.6 55.5 21.5 58.3 23.3 0.001
13.4 1.7 13.4 1.6 13.6 1.7 0.001
169 37.4 172 40.1 180 42.6 0.001
48.2 57.9 64.4 0.001
58.7 55.9 51.1 0.001
26.2 28.1 29.4 0.001
11.8 13.3 16.4 0.001
1.5 1.3 2.6 0.03
1.5 1.6 1.6 0.001
84.0 84.1 86.4 0.004
59.9 61.1 62.3 0.67
56.8 60.5 59.2 0.001
index; COPD  chronic obstructive pulmonary disease; GFR  glomerular filtration rate; HbA1C 
essure; TZD thiazolidinedione.7
y mass 0.001]).
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July 28, 2009:422–8 HbA1C and Mortality in Diabetic HFAdditional analyses (data not shown) demonstrated sim-
lar relationships between HbA1C quintiles and mortality
hen patients were stratified according to LVEF (preserved
r mildly reduced vs. moderate to severely reduced), renal
nsufficiency (GFR 60 ml/min/m2 vs. 60 ml/min/m2),
dvanced age (age65 years vs.65 years), and insulin use.
F and all-cause hospitalization. The incidence of HF
ospitalization over 2 years increased with increasing levels
f HbA1C (Fig. 2, Table 2). In adjusted analyses (using Q1
s the reference group), the hazard of HF hospitalization
ncreased with increasing quintiles, but this hazard was no
onger statistically significant after adjustment for potential
onfounders (Table 2).
Similarly, the incidence of all-cause hospitalization in-
reased across the HbA1C quintiles. In total, 550 (43.5%)
1 patients, 491 (42.6%) Q2 patients, 492 (45.1%) Q3
atients, 564 (47.1%) Q4 patients, and 572 (51.6 %) Q5
atients were hospitalized for any cause during the 2 years of
ollow-up. After adjustments for potential confounders,
here was a trend toward increased all-cause hospitalization
n the highest quintile (Q5) when compared with the lowest
uintile (Q1) (risk-adjusted HR: 1.12, 95% CI: 0.99 to
.26, p  0.08). The hazard ratios for the other quintiles
ere not significantly different than the first quintile (data
ot shown).
Figure 1 Proportion of Patients Who Died
at 2-Year Follow-Up by Quintiles of HbA1C
The graph represents the proportion of patients who died at 2-year follow-up by
quintiles (Q) of glycosylated hemoglobin (HbA1C). Global chi-square p  0.001.
Error bars indicate the 95% confidence intervals.
utcomesTable 2 Outcomes
Outcome
Quintile 1
HbA1C <6.4%
(n  1,264)
Quintile 2
6.4% < HbA1C <7.1%
(n  1,152)
7
Death, n (%) 316 (25.0) 265 (23.0) 19
Unadjusted HR (95% CI)* 1.00 0.89 (0.76–1.05, p 0.17) 0.6
Adjusted HR (95% CI)*† 1.00 0.96 (0.81–1.13, p 0.63) 0.7
HF hospitalization, n (%) 168 (13.3) 151 (13.1) 16
Unadjusted HR (95% CI)* 1.00 0.96 (0.77–1.20, p 0.72) 1.1
Adjusted HR (95% CI)*† 1.00 1.01 (0.81–1.26, p 0.96) 1.1Quintile 1 is the reference group. †Text describes multivariable model.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.iscussion
n a cohort of ambulatory patients with established HF who
ere receiving medical treatment for diabetes, the relation-
hip between mortality and HbA1C was U-shaped. Indi-
iduals in the middle quintile with modest glycemic control
7.1%  HbA1C 7.8%) had the lowest mortality when
ompared with individuals in the other quintiles of HbA1C.
lthough the rates of HF hospitalization increased with
ncreasing levels of HbA1C, this crude relationship was no
onger statistically significant after adjustment for potential
onfounders, suggesting that the associated baseline demo-
raphic and treatment differences seen in patients with
levated HbA1c levels may be accounting for the increased
ates of HF hospitalization.
Although elevated HbA1C has been associated with
ncreased risk of adverse cardiovascular events in the general
opulation (15), the relationship between HbA1C levels
nd prognosis in diabetic patients with established HF has
een less well studied. A recent analysis of 2,412 HF
articipants (of which only 907 participants had prior
iabetes) enrolled in the CHARM (Candesartan in Heart
ailure: Assessment of Reduction in Mortality and morbid-
ty) study (18) demonstrated that the adjusted risks of total
ortality, HF hospitalization, and a composite outcome of
ardiovascular death or HF hospitalization increased pro-
ressively with increasing levels of HbA1C. Of note, this
elationship between HbA1C levels and death in the
HARM study was more pronounced in the nondiabetic
atients enrolled in CHARM and did not reach statistical
ignificance for the outcomes of cardiovascular death (p for
eterogeneity  0.04) and total mortality (p for heteroge-
eity  0.008) in the 907 patients with prior diabetes after
djustment for differences in baseline characteristics. Addi-
ionally, in a smaller study of 123 diabetic patients with
dvanced systolic HF referred to a HF management pro-
ram, a paradoxical relationship between HbA1C levels and
ortality was identified (17). In this study of 123 patients
ith advanced systolic HF, an HbA1C level 7% was
ssociated with an increased risk of death when compared
ith a level of 7%, even after adjustments for potential
onfounders.
Quintile 3
HbA1C <7.8%
 1,092)
Quintile 4
7.8% < HbA1C <9.0%
(n  1,198)
Quintile 5
HbA1C >9.0%
(n  1,109)
7) 269 (22.5) 257 (23.2)
6–0.80, p 0.001) 0.87 (0.74–1.03, p 0.11) 0.91 (0.77–1.07, p 0.26)
1–0.88, p 0.001) 0.96 (0.81–1.13, p 0.61) 1.06 (0.90–1.26, p 0.48)
5) 196 (16.4) 202 (18.2)
2–1.41, p 0.24) 1.22 (0.99–1.49, p 0.06) 1.39 (1.13–1.70, p 0.002)
2–1.41, p 0.25) 1.11 (0.90–1.37, p 0.34) 1.17 (0.94–1.44, p 0.16).1% <
(n
3 (17.
7 (0.5
3 (0.6
9 (15.
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HbA1C and Mortality in Diabetic HF July 28, 2009:422–8Our data add to this existing body of published reports
nd support a more complex relationship between HbA1C
nd mortality in diabetic patients with established HF. By
tudying a large sample of ambulatory HF patients with
stablished diabetes, we demonstrate that patients in the
ower and higher HbA1C quintiles have a higher mortality
han patients with modest glycemic control (7.1% 
bA1C 7.8%). The increased mortality associated with
he higher HbA1C levels is likely multifactorial and may
nclude both direct and indirect effects of hyperglycemia.
otential adverse effects of hyperglycemia include increased
ndothelial dysfunction (22), increased oxidative stress (23),
ncreased protein kinase C activation (24), and potentially
ccelerated atherosclerosis. In addition, increased advanced
lycation end products, as a result of chronic hyperglycemia,
ay lead to a variety of detrimental processes such as
ncreased myocardial stiffness (25) and activation of the
eceptor for advanced glycation end products that in turn
eads to up-regulation of cellular signals that lead to cellular
ysfunction (26,27). Also, elevated levels of HbA1C may be
marker for a greater degree of insulin resistance with the
ssociated derangements of cardiac metabolism and myo-
ardial energy utilization in the insulin-resistant myocar-
ium (28) and increased activation of the sympathetic nervous
ystem (29). Finally, elevated HbA1C levels may also be
eflective of poor compliance with medications that in turn
ay be associated with poor outcomes.
In addition to the increased risk of death in the higher
bA1C quintiles, we also demonstrate that lower quintiles
f HbA1C are associated with an increased mortality when
ompared with modest glycemic control (7.1%  HbA1C
7.8%). There are several possible explanations for these
ndings. First, intensive glucose therapy to achieve normal
r near-normal HbA1C levels may be hazardous in diabetic
atients with established HF. In the recently completed
CCORD (Action to Control Cardiovascular Risk in
Figure 2 Proportion of Patients With HF
Hospitalization at 2-Year Follow-Up by Quintiles
The graph represents the proportion of patients with heart failure (HF) hospital-
ization at 2-year follow-up by quintiles. Global chi-square p  0.002. Error bars
indicate the 95% confidence intervals. Abbreviations as in Figure 1.iabetes) trial (30), a strategy of intensive glucose control Hargeting normal levels of HbA1C (below 6%) to reduce
ardiovascular events was compared with standard therapy
targeting a level from 7.0% to 7.9%) in patients with type
diabetes and either established cardiovascular disease or
dditional cardiovascular risk factors. In the ACCORD
rial, there was an unexpected increase in mortality in
atients assigned to the intensive treatment arm with no
ignificant reduction in major cardiovascular events when
ompared with mortality of patients receiving standard care.
ur data differ from the ACCORD trial in that patients
ho achieved the lowest HbA1C levels in ACCORD were
lso receiving more antihyperglycemic medications than
hose in the standard therapy group. Nonetheless, our data,
n a higher-risk population, are consistent with the unex-
ected hazard associated with a strategy of intensive glucose
ontrol that was seen in the ACCORD study. A second
ossible explanation for our findings includes “reverse epi-
emiology” (31,32). This concept refers to the observation
f several, paradoxical relationships between conventional
ardiovascular risk factors and clinical outcomes in patients
ith established HF. Such risk factors have included obesity
nd hypercholesterolemia, in which higher levels of body
eight or cholesterol are paradoxically associated with
ncreased survival in patients with established HF (31).
lthough there are several potential causes for this risk
actor pattern, more commonly proposed explanations in-
lude the association of lower weight and lower cholesterol
ith increased protein energy malnutrition and an increased
nflammatory syndrome associated with cardiac cachexia
31,32). Of note, the mean body mass index was slightly
ower in the lowest HbA1C quintile in this study, but the
ssociation between HbA1C and mortality remained statis-
ically significant after adjusting for small differences in body
ass index. Another potential explanation for our findings
s that low HbA1C is a marker for more advanced or severe
F or a marker for older patients with more comorbid conditions.
t is important to note that functional status was not
vailable in this cohort, but patients in the lowest HbA1C
uintile were more likely to have preserved LVEF than
hose patients with increased HbA1C levels. Finally, low
bA1C may not be an adequate marker of glycemic control
nd/or may be reflective of an unmeasured variable that may
e contributing to adverse events.
tudy limitations. The present study has several limita-
ions. First, the study is an observational study with the
nherent limitations of this type of study design. Multiva-
iable statistical models were used to adjust for heterogene-
ty between HbA1C groups, but residual unmeasured con-
ounding may remain. However, availability of data on
VEF, pharmacy data (including diabetic therapy), and
aboratory data should provide robust risk-adjustment vari-
bles. In addition, these data were collected as part of a
ational clinical database at VA medical centers, and mea-
urements of HbA1C were performed in a clinical setting
nd not in a standardized laboratory. Also, the most recent
bA1C value within 1 year before and up to 2 weeks after
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July 28, 2009:422–8 HbA1C and Mortality in Diabetic HFhe index visit were used as the baseline value. Future,
ppropriately designed prospective studies with standard-
zed measurements of baseline HbA1C will be necessary to
onfirm our findings.
Despite these limitations, these data have several strengths.
he large sample size of this study population allows
tratification of the data by HbA1C levels in order to
dentify the complex, nonlinear relationship between
bA1C and mortality. Although this study was not a
rospectively designed study to test the association between
bA1C and outcomes in HF patients, the observational
tudy highlights an association seen in a real-world setting
f clinical care. Finally, our study provides timely data in
ight of the recently published ACCORD results, which
emonstrated a previously unrecognized harm of strategy of
ight glycemic control in high-risk patients with type 2
iabetes (30).
onclusions
n a large national cohort of patients with diabetes and
stablished HF, we demonstrate that the association be-
ween levels of HbA1C and mortality appears U-shaped,
ith increased risk of death at both higher and lower
bA1C levels when compared with modest glucose control
7.1%  HbA1C 7.8). It is estimated that approximately
0% to 30% (8), and perhaps up to 45% (9), of the nearly 5
illion individuals with HF in the U.S. have coexisting
iabetes. Therefore, we feel that our data have significant
ublic health implications. We confirm that significantly
levated HbA1C is associated with increased risk in this
opulation and efforts should be made to treat these patients
ith proven HF therapies and consider glucose-lowering
herapy. Importantly, we also demonstrate an unexpected
azard with normal or near-normal HbA1C levels in this
igh-risk population of patients with diabetes and HF.
lthough this study is an observational study and does not
est an active treatment strategy targeting lowering HbA1C
evels in diabetic patients with HF, our data are consistent
ith the ACCORD trial data and demonstrate that low
bA1C levels in this high-risk population are associated
ith increased risk of death. Future appropriately designed
tudies are necessary to confirm our findings and expand on
otential mechanisms contributing to the increased hazard.
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